Expose Hidden Corporate Lobbying By Eli Lilly
Despite saying it supported lower drug prices, Eli Lilly spent tens of millions of dollars lobbying over the last decade — including fighting against legislation to reduce the price of insulin and other life-saving prescription drugs. Now, a group of shareholders have filed a proposal that would make Eli Lilly be fully transparent about its lobbying activities and reveal whether its behind-closed-doors lobbying matches its public statements.
This lobbying transparency proposal will be voted on at Eli Lilly’s annual shareholder meeting, to be held virtually on May 6, 2024, starting at 8:30 AM Eastern Time. Here is the information to attend this meeting: ELI LILLY AND COMPANY’s Virtual Shareholder’s Meeting – Pre meeting message page (virtualshareholdermeeting.com)
The Lobbying Transparency Shareholder proposal is ITEM 6 – available along with other shareholder proposals and information at this link to view the 2024 Eli Lilly Proxy Statement: https://investor.lilly.com/static-files/39383ed4-8b4b-43bf-901d-a094a82d3d0c
